Trials / Completed
CompletedNCT02690337
Study of DS-1123a in Advanced Solid Tumours
Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of DS-1123a in Japanese subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS-1123 | starting intravenous (IV) dose of 0.1 mg/kg. |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2016-02-24
- Last updated
- 2018-12-24
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02690337. Inclusion in this directory is not an endorsement.